Clinical Research Directory
Browse clinical research sites, groups, and studies.
Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of different neoadjuvant immunotherapies in non-small cell lung cancer (NSCLC) patients using the real-world data. The main questions it aims to answer are: * What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment? * How to determine the subgroups of patients benefit from neoadjuvant immunotherapy? Participants will receive neoadjuvant immunotherapy the study will analyze the real-world data.
Official title: Real-world Clinical Outcomes of Neoadjuvant Immunotherapy in NSCLC Patients: A Retrospective, Multi-center, Cohort Study (NeoIM-Lung)
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
OBSERVATIONAL
Enrollment
4000
Start Date
2024-03-01
Completion Date
2034-12-31
Last Updated
2024-07-03
Healthy Volunteers
No
Conditions
Interventions
Neoadjuvant immunotherapy
Immune checkpoint inhibitors are used as neoadjuvant settings for NSCLC patients.
Other drugs for neoadjuvant treatment
Drugs other than immune checkpoint inhibitors are being used as a new adjuvant setting for patients with NSCLC.
Locations (1)
Shugeng Gao
Beijing, Beijing Municipality, China